Characterizing Glioblastoma Heterogeneity via Single-Cell Receptor Quantification
Si Chen1, Thien Le2, Brendan A C Harley3,4
1Department of Bioengineering, University of Illinois at Urbana-Champaign, Champaign, IL, United States.
Abstract:
Dysregulation of tyrosine kinase receptor (RTK) signaling pathways play important roles in glioblastoma (GBM). However, therapies targeting these signaling pathways have not been successful, partially because of drug resistance. Increasing evidence suggests that tumor heterogeneity, more specifically, GBM-associated stem and endothelial cell heterogeneity, may contribute to drug resistance. In this perspective article, we introduce a high-throughput, quantitative approach to profile plasma membrane RTKs on single cells. First, we review the roles of RTKs in cancer. Then, we discuss the sources of cell heterogeneity in GBM, providing context to the key cells directing resistance to drugs. Finally, we present our provisionally patented qFlow cytometry approach, and report results of a "proof of concept" patient-derived xenograft GBM study.
Insights
Glioblastoma (GBM) drug resistance may stem from cell diversity. A new qFlow cytometry method profiles plasma membrane tyrosine kinase receptors (RTKs) on single cells to understand this heterogeneity and guide future therapies.
Area of Science:
- Oncology
- Cell Biology
- Biotechnology
Background:
- Dysregulated tyrosine kinase receptor (RTK) signaling is crucial in glioblastoma (GBM) development.
- Therapeutic resistance in GBM is a significant challenge, potentially linked to tumor cell heterogeneity.
- Glioblastoma-associated stem cells and endothelial cells contribute to this heterogeneity and drug resistance.
Purpose of the Study:
- To introduce a high-throughput, quantitative method for profiling plasma membrane RTKs on single GBM cells.
- To explore the role of cell heterogeneity in GBM drug resistance.
- To present a novel qFlow cytometry approach for analyzing RTK expression.
Main Methods:
- Review of RTK roles in cancer.
- Discussion of GBM cell heterogeneity sources.
- Application of a provisionally patented qFlow cytometry technique for single-cell RTK profiling.
- Proof-of-concept study using patient-derived xenograft GBM models.
Main Results:
- Demonstrated a high-throughput, quantitative method for single-cell RTK profiling.
- Provided insights into GBM cell heterogeneity and its link to drug resistance.
- Successfully applied the qFlow cytometry approach in a patient-derived xenograft model.
Conclusions:
- Single-cell RTK profiling offers a powerful approach to dissect GBM heterogeneity.
- Understanding cell diversity is key to overcoming therapeutic resistance in glioblastoma.
- The qFlow cytometry method shows promise for guiding personalized GBM treatment strategies.
Related Concept Videos
Types of Receptors: Cell Surface Receptors
Internal Receptors
Receptor-mediated Endocytosis
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
G-protein Coupled Receptors
Types of Receptors: Internal Receptors
Similar to membrane-bound receptors, the binding of a ligand to the intracellular receptor of causes a conformational change in the...


